Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study
| Autor: | Monica Regine Romstad, Hans-Johnny Schjelderup Nilsen, Marianne Bollestad, Gunnar Skov Simonsen, Janne Møller-Stray, Arne Søraas, Niclas Raffelsberger, Einar Tollaksen Weme, Pål A. Jenum, Yngvar Tveten, Andreas Emmert, Nina Handal, Synne Jenum, Sigrid Solhaug, Nils Grude, Morten Lindbæk |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
0301 basic medicine Microbiology (medical) medicine.medical_specialty Adolescent medicine.drug_class Urinary system 030106 microbiology Antibiotics Anti-Infective Agents Urinary Bacteriuria beta-Lactamases Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Outpatients Escherichia coli medicine Humans Pharmacology (medical) Prospective Studies 030212 general & internal medicine Prospective cohort study Escherichia coli Infections Aged Aged 80 and over Pharmacology Norway business.industry Amdinocillin Pivoxil Bacteriological Cure Middle Aged bacterial infections and mycoses medicine.disease Pivmecillinam Treatment Outcome Infectious Diseases chemistry Urinary Tract Infections Female Observational study business Cohort study |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 73:2503-2509 |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/dky230 |
| Popis: | Objectives To compare the clinical and bacteriological outcomes of pivmecillinam treatment for community-acquired urinary tract infections (UTIs) caused by ESBL-producing Escherichia coli versus non-ESBL-producing E. coli in an outpatient setting. Methods A prospective, multicentre, observational cohort study of women aged ≥16 years, with pivmecillinam-treated community-acquired UTIs caused by E. coli with or without ESBL production, recruited from primary care, was conducted in the period from April 2013 to August 2016. Eighty-eight women (mean age 49.4 years) with community-acquired UTIs caused by ESBL-producing E. coli were compared with a control group of 74 women (mean age 50.1 years). Trial registration Regional Committees for Medical and Health Research Ethics (REC) in Norway, ID 2011/2214, and ClinicalTrials.gov, ID NCT01531023. Results The median time until symptom resolution after treatment initiation was 5 days for the ESBL cases and 3 days for the non-ESBL controls (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|